-
1
-
-
67650745310
-
-
Ernst ME. Parkinson's Disease. In: Dunsworth T, Richardson M, Cheng J, et al, eds. Pharmacotherapy Self-Assessment Program, 6th ed. Neurology and Psychiatry. Lenexa, KS: American College of Clinical Pharmacy, 2007: 19-33
-
Ernst ME. Parkinson's Disease. In: Dunsworth T, Richardson M, Cheng J, et al, eds. Pharmacotherapy Self-Assessment Program, 6th ed. Neurology and Psychiatry. Lenexa, KS: American College of Clinical Pharmacy, 2007: 19-33
-
-
-
-
2
-
-
33646076457
-
Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology
-
Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronset G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
-
(2006)
Neurology
, vol.66
, pp. 983-995
-
-
Pahwa, R.1
Factor, S.A.2
Lyons, K.E.3
Ondo, W.G.4
Gronset, G.5
Bronte-Stewart, H.6
-
3
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
-
Jadad A.R., Moore A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
-
(1996)
Control Clin Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, A.2
Carroll, D.3
Jenkinson, C.4
Reynolds, D.J.M.5
Gavaghan, D.J.6
-
5
-
-
0026776749
-
Variance imputation for overviews of clinical trials with continuous response
-
Follmann D., Elliott P., Suh I., and Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45 (1992) 769-773
-
(1992)
J Clin Epidemiol
, vol.45
, pp. 769-773
-
-
Follmann, D.1
Elliott, P.2
Suh, I.3
Cutler, J.4
-
6
-
-
0030880324
-
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
-
Baas H., Beiske A.G., Ghika J., Jackson M., Oertel W.H., Poewe W., et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63 4 (1997) 421-428
-
(1997)
J Neurol Neurosurg Psychiatry
, vol.63
, Issue.4
, pp. 421-428
-
-
Baas, H.1
Beiske, A.G.2
Ghika, J.3
Jackson, M.4
Oertel, W.H.5
Poewe, W.6
-
7
-
-
0030833203
-
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment
-
Waters C.H., Kurth M., Bailey P., Shulman L.M., LeWitt P., Dorflinger E., et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49 (1997) 665-671
-
(1997)
Neurology
, vol.49
, pp. 665-671
-
-
Waters, C.H.1
Kurth, M.2
Bailey, P.3
Shulman, L.M.4
LeWitt, P.5
Dorflinger, E.6
-
8
-
-
19244365858
-
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study
-
Fenelon G., Gimenez-Roldan S., Montastruc J.L., Bermejo F., Durif F., Bourdeix I., et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 110 (2003) 239-251
-
(2003)
J Neural Transm
, vol.110
, pp. 239-251
-
-
Fenelon, G.1
Gimenez-Roldan, S.2
Montastruc, J.L.3
Bermejo, F.4
Durif, F.5
Bourdeix, I.6
-
9
-
-
12744272177
-
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations
-
Reichmann H., Boas J., MacMahon D., Myllyla V., Hakala A., Reinikainen K., et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111 (2005) 21-28
-
(2005)
Acta Neurol Scand
, vol.111
, pp. 21-28
-
-
Reichmann, H.1
Boas, J.2
MacMahon, D.3
Myllyla, V.4
Hakala, A.5
Reinikainen, K.6
-
10
-
-
5344247928
-
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
-
Olanow C.W., Kieburtz K., Stern M., Watts R., Langston J.W., Guarnieri M., et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 61 (2004) 1563-1568
-
(2004)
Arch Neurol
, vol.61
, pp. 1563-1568
-
-
Olanow, C.W.1
Kieburtz, K.2
Stern, M.3
Watts, R.4
Langston, J.W.5
Guarnieri, M.6
-
11
-
-
0041704637
-
Entacapone is beneficial in both fluctuating and non-fluctuation patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
-
Brooks D.J., Sagar H., and The UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuation patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74 (2003) 1071-1079
-
(2003)
J Neurol Neurosurg Psychiatry
, vol.74
, pp. 1071-1079
-
-
Brooks, D.J.1
Sagar, H.2
The UK-Irish Entacapone Study Group3
-
12
-
-
0035099631
-
Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone
-
Shan D.E., Lee S.J., Chao L.Y., and Yeh S.I. Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone. Can J Neurol Sci 28 (2001) 70-75
-
(2001)
Can J Neurol Sci
, vol.28
, pp. 70-75
-
-
Shan, D.E.1
Lee, S.J.2
Chao, L.Y.3
Yeh, S.I.4
-
13
-
-
0036113588
-
. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)
-
Poewe W.H., Deuschl G., Gordin A., Kultalahti E.R., Leinonen M., and the Celomen Study Group. . Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 (2002) 245-255
-
(2002)
Acta Neurol Scand
, vol.105
, pp. 245-255
-
-
Poewe, W.H.1
Deuschl, G.2
Gordin, A.3
Kultalahti, E.R.4
Leinonen, M.5
the Celomen Study Group6
-
14
-
-
15844386001
-
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial
-
Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2005) 947-954
-
(2005)
Lancet
, vol.365
, pp. 947-954
-
-
Rascol, O.1
Brooks, D.J.2
Melamed, E.3
Oertel, W.4
Poewe, W.5
Stocchi, F.6
-
15
-
-
0034519674
-
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa
-
Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23 6 (2000) 324-330
-
(2000)
Clin Neuropharmacol
, vol.23
, Issue.6
, pp. 324-330
-
-
Rabey, J.M.1
Sagi, I.2
Huberman, M.3
Melamed, E.4
Korczyn, A.5
Giladi, N.6
-
16
-
-
2342426425
-
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study
-
Waters C.H., Sethi K.D., Hauser R.A., Molho E., Bertoni J.M., and The Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19 4 (2004) 426-432
-
(2004)
Mov Disord
, vol.19
, Issue.4
, pp. 426-432
-
-
Waters, C.H.1
Sethi, K.D.2
Hauser, R.A.3
Molho, E.4
Bertoni, J.M.5
The Zydis Selegiline Study Group6
-
17
-
-
33646686620
-
Selegiline slows the progression of the symptoms of Parkinson disease
-
Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Maki-Ikola O., Palm R., et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006) 1200-1206
-
(2006)
Neurology
, vol.66
, pp. 1200-1206
-
-
Palhagen, S.1
Heinonen, E.2
Hagglund, J.3
Kaugesaar, T.4
Maki-Ikola, O.5
Palm, R.6
-
18
-
-
0036231440
-
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
-
Shoulson I., Oakes D., Fahn S., Lang A., Langston W., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 (2002) 604-612
-
(2002)
Ann Neurol
, vol.51
, pp. 604-612
-
-
Shoulson, I.1
Oakes, D.2
Fahn, S.3
Lang, A.4
Langston, W.5
LeWitt, P.6
-
19
-
-
33748320447
-
Minimal clinically important change on the unified Parkinson's disease rating scale
-
Schrag A., Sampaio C., Counsell N., and Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 12 8 (2006) 1200-1207
-
(2006)
Mov Disord
, vol.12
, Issue.8
, pp. 1200-1207
-
-
Schrag, A.1
Sampaio, C.2
Counsell, N.3
Poewe, W.4
-
20
-
-
33748360763
-
Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need
-
Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 21 (2006) 1059-1061
-
(2006)
Mov Disord
, vol.21
, pp. 1059-1061
-
-
Rascol, O.1
-
21
-
-
34547530313
-
Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art
-
Rapaport M.H. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry 68 Suppl. 8 (2007) 42-46
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.SUPPL. 8
, pp. 42-46
-
-
Rapaport, M.H.1
|